TcLand Expression Launches a Multicenter Clinical Validation Study on Its K-RejX Diagnostic Blood Test
News Oct 14, 2009
TcLand Expression SA has announced the launch of the KARE study (Kidney Allograft REjection).
This will be the international, multicentre, prospective clinical validation study for TcLand Expression’s K-RejX qPCR blood test, as a multi-gene molecular diagnostic tool to help in the identification of kidney transplant recipients at risk of chronic antibody-mediated rejection (CAMR). The KARE study will enroll 450 patients from over 30 European and North American large transplantation centers.
All in a Droplet: Atomic Resolution of ALS Protein ResolvedNews
Researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases of muscle and bone.READ MORE